文献速递血脂与心血管预防

Evolocumab 在 HIV 感染合并血脂异常患者中的随机双盲 BEIJERINCK 研究主要结果

Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
PubMed 文献 · J Am Coll Cardiol · 2020-03-28

BEIJERINCK 研究是一项随机双盲多国试验,在已接受最大耐受剂量他汀治疗 HIV 感染合并高胆固醇/混合型血脂异常患者中比较每月皮下 evolocumab 420 mg 与安慰剂。共分析 464 例患者,evolocumab 较安慰剂使 LDL-C 从基线至第 24 周降低 56.9%(95%CI:61.6% 至 52.3%),73.3% 患者达到 LDL-C<70 mg/dl(安慰剂组 7.9%)。evolocumab 耐受良好,治疗中出现的不良事件患者发生率两组相似。

要点

  • evolocumab 使 HIV 合并血脂异常患者 LDL-C 较安慰剂降低 56.9%(95%CI:61.6% 至 52.3%)。
  • 73.3% 的 evolocumab 组患者达到 LDL-C<70 mg/dl,安慰剂组为 7.9%。
  • evolocumab 耐受良好,治疗中出现的不良事件患者发生率与安慰剂组相似。

核心结论

  • 在已接受最大耐受剂量他汀治疗的 HIV 感染合并血脂异常患者中,evolocumab 安全且显著降低血脂水平。
  • evolocumab 是降低高心血管风险 HIV 感染者致动脉粥样硬化脂蛋白的有效治疗。

研究设计与样本

  • BEIJERINCK 为随机、双盲、多国试验,比较每月皮下 evolocumab 420 mg 与安慰剂。
  • 研究对象为接受最大耐受剂量他汀治疗、合并高胆固醇血症/混合型血脂异常的 HIV 感染者。
  • 共分析 464 例患者,平均年龄 56.4 岁,82.5% 为男性,平均 HIV 感染病程 17.4 年。

主要发现

  • evolocumab 较安慰剂使 LDL-C 从基线至第 24 周降低 56.9%(95%CI:61.6% 至 52.3%)。
  • evolocumab 组 73.3% 患者达到 LDL-C<70 mg/dl,安慰剂组为 7.9%。
  • evolocumab 还显著降低非高密度脂蛋白胆固醇、载脂蛋白 B 和脂蛋白(a)(均 p<0.0001)。
  • evolocumab 耐受良好,治疗中出现的不良事件患者发生率在 evolocumab 与安慰剂组相似。

关键数值与推荐

  • 主要终点为 LDL-C 从基线至第 24 周的百分比变化。
  • 次要终点包括达到 LDL-C<70 mg/dl 的比例及其他血浆脂质和脂蛋白水平的百分比变化。

临床怎么用

  • 对于接受最大耐受剂量他汀治疗但血脂仍不达标的 HIV 感染合并血脂异常患者,可考虑 evolocumab 以显著降低 LDL-C。
  • evolocumab 在该人群中耐受良好,治疗中出现的不良事件患者发生率与安慰剂相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People living with human immunodeficiency virus (PLHIV) are at increased risk of atherosclerotic cardiovascular disease (ASCVD) and are prone to statin-related adverse events from drug-drug interactions with certain antiretroviral regimens. OBJECTIVES: This study sought to evaluate the efficacy and safety of evolocumab in dyslipidemic PLHIV. METHODS: BEIJERINCK (EvolocumaB Effect on LDL-C Lowering in SubJEcts with Human Immunodeficiency VirRus and INcreased Cardiovascular RisK) is a randomized, double-blind, multinational trial comparing monthly subcutaneous evolocumab 420 mg with placebo in PLHIV with hypercholesterolemia/mixed dyslipidemia taking maximally-tolerated statin therapy. The primary endpoint was the percent change (baseline to week 24) in low-density lipoprotein cholesterol (LDL-C); secondary endpoints included achievement of LDL-C <70 mg/dl and percent change in other plasma lipid and lipoprotein levels. Treatment-emergent adverse events were also examined. RESULTS: A total of 464 patients were analyzed (mean age of 56.4 years, 82.5% male, mean duration with HIV of 17.4 years). ASCVD was documented in 35.6% of patients, and statin intolerance/contraindications to statin use were present in 20.7% of patients. Evolocumab reduced LDL-C by 56.9% (95% confidence interval: 61.6% to 52.3%) from baseline to week 24 versus placebo. An LDL-C level of <70 mg/dl was achieved in 73.3% of patients in the evolocumab group versus 7.9% in the placebo group. Evolocumab also significantly reduced other atherogenic lipid levels, including non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) (all p < 0.0001). Evolocumab was well tolerated, and treatment-emergent adverse events patient incidence was similar among evolocumab and placebo groups. CONCLUSIONS: Evolocumab was safe and significantly reduced lipid levels in dyslipidemic PLHIV on maximally-tolerated statin therapy. Evolocumab is an effective therapy for lowering atherogenic lipoproteins in PLHIV with high cardiovascular risk. (Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia; NCT02833844).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Boccara F, Kumar PN, Caramelli B, et al. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study. J Am Coll Cardiol. 2020. PMID: 32234462. doi:10.1016/j.jacc.2020.03.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。